Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight
breast cancer by blocking the production of estrogen by the tumor cells. Biological therapies
such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of
advanced solid tumors. Combining anastrozole with ZD 1839 may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining anastrozole with ZD 1839 in
treating postmenopausal women who have metastatic breast cancer that has not responded to
hormone therapy.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio